AJP - Endo Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab (June 12, 2007). doi:10.1152/ajpendo.00171.2007
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
293/2/E492    most recent
00171.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Coenen, K. R
Right arrow Articles by Hasty, A. H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coenen, K. R
Right arrow Articles by Hasty, A. H
Submitted on March 15, 2007
Accepted on June 7, 2007

Obesity Potentiates Development of Fatty Liver and Insulin Resistance, but Not Atherosclerosis in High Fat Diet-Fed Agouti LDLR Deficient Mice

Kimberly R Coenen1 and Alyssa H Hasty2*

1 Molecular Physiology and Biophysics, Vanderbilt University Medical Center, Nashville, Tennessee, United States
2 Molecular Physiology & Biophysics, Vanderbilt University Medical Center, Nashville, Tennessee, United States

* To whom correspondence should be addressed. E-mail: alyssa.hasty{at}vanderbilt.edu.

Obesity is increasing at an alarming rate, and its related disorders are placing a considerable strain on our healthcare system. Although they are not always coincident, obesity is often accompanied by hyperlipidemia. Both obesity and hyperlipidemia are independently associated with atherosclerosis, non-alcoholic fatty liver disease (NAFLD), and insulin resistance (IR). Thus, we sought to determine the relative contributions of obesity and hyperlipidemia to these associated pathologies. Obese agouti (Ay/a) mice and their littermate controls (a/a) were placed on an LDLR-/- background. At four months of age, mice were either maintained on chow diet (CD) or placed on Western diet (WD) for 12 weeks. These genetic and dietary manipulations yielded four experimental groups: 1) Lean- a/a;LDLR-/-CD; 2) genetic-induced obesity (GIO)- Ay/a;LDLR-/-CD; 3) diet-induced obesity (DIO)- a/a;LDLR-/-WD; and 4) genetic- plus diet-induced obesity (GIO/DIO)- Ay/a;LDLR-/-WD. Lipoprotein profiles revealed increased VLDL and LDL particles in WD-fed mice compared to CD-fed controls. The hyperlipidemia present in this mouse model was the result of both increased hepatic triglyceride production and delayed lipoprotein clearance from the plasma. Both WD-fed groups exhibited similar levels of atherosclerotic lesion area, with increased obesity in the GIO/DIO group having no impact on atherogenesis. However, the severe obesity in the GIO/DIO group did aggravate NAFLD and IR. These findings suggest that while obesity and hyperlipidemia exert individual pathological effects, the combination of the two has the potential to exert an additive effect on NAFLD and IR, but not atherosclerosis in this mouse model.




This article has been cited by other articles:


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
X. Qi, J. T. Reed, G. Wang, S. Han, E. W. Englander, and G. H. Greeley Jr.
Ghrelin secretion is not reduced by increased fat mass during diet-induced obesity
Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2008; 295(2): R429 - R435.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
D. J. Lloyd, J. McCormick, J. Helmering, K. W. Kim, M. Wang, P. Fordstrom, S. A. Kaufman, R. A. Lindberg, and M. M. Veniant
Generation and characterization of two novel mouse models exhibiting the phenotypes of the metabolic syndrome: Apob48-/-Lepob/ob mice devoid of ApoE or Ldlr
Am J Physiol Endocrinol Metab, March 1, 2008; 294(3): E496 - E505.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
A. M. Nuotio-Antar, D. L. Hachey, and A. H. Hasty
Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice
Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1517 - E1528.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 2007 by the American Physiological Society.